» Articles » PMID: 37576432

Evidence in Humans for Bone As an Endocrine Organ Regulating Energy Metabolism

Overview
Specialty Endocrinology
Date 2023 Aug 14
PMID 37576432
Authors
Affiliations
Soon will be listed here.
Abstract

There is increasing evidence from animal models that bone, in addition to its traditional function of providing structural support for the organism, has a rich network of interactions with multiple other tissues. This perspective focuses on evidence from human studies demonstrating that bone is an endocrine organ regulating energy metabolism, with the specific examples being osteocalcin, lipocalin 2, RANKL, and sclerostin. Conversely, animal studies have also demonstrated that a key hormone regulating energy metabolism, leptin, regulates bone metabolism via the sympathetic nervous system. Studies in humans have established a role for the sympathetic nervous system in regulating bone turnover; indeed, the potential therapeutic benefit of targeting this pathway in humans to prevent postmenopausal bone loss is currently being evaluated.

Citing Articles

Characterizing Bone Phenotypes Related to Skeletal Fragility Using Advanced Medical Imaging.

Whittier D, Bevers M, Geusens P, van den Bergh J, Gabel L Curr Osteoporos Rep. 2023; 21(6):685-697.

PMID: 37884821 PMC: 10724303. DOI: 10.1007/s11914-023-00830-6.

References
1.
Toulis K, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian J . β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int. 2013; 25(1):121-9. DOI: 10.1007/s00198-013-2498-z. View

2.
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle W, Lacey D, Riggs B . Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003; 111(8):1221-30. PMC: 152939. DOI: 10.1172/JCI17215. View

3.
Lyu H, Zhao S, Zhang L, Wei J, Li X, Li H . Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. BMJ. 2023; 381:e073435. PMC: 10111187. DOI: 10.1136/bmj-2022-073435. View

4.
Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S . RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest. 2019; 129(8):3214-3223. PMC: 6668701. DOI: 10.1172/JCI125915. View

5.
Farr J, Charkoudian N, Barnes J, Monroe D, McCready L, Atkinson E . Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women. J Clin Endocrinol Metab. 2012; 97(11):4219-27. PMC: 3485606. DOI: 10.1210/jc.2012-2381. View